SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC
European Journal of Cancer · 2026-11 · 248 · 117618
DOI: 10.1016/j.ejca.2026.117618 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von J. Kim und 18 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kim, J., Park, Y., Lee, O., Lee, C., Lee, W., Kim, K., Kim, S., Lee, H., Ullapu, P., Goo, M., Lee, H., Oh, Y., Choi, S., Cho, J., Choi, S., Lee, D., Jeon, S., Ryu, K., & Kim, M. (2026). SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC. European Journal of Cancer, 248, 117618. https://doi.org/10.1016/j.ejca.2026.117618
Vancouver
Kim J, Park Y, Lee O, Lee C, Lee W, Kim K, et al. SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC. European Journal of Cancer. 2026;248:117618. doi:10.1016/j.ejca.2026.117618
BibTeX
@article{Kim2026,
author = {Kim, J. and Park, Y.J. and Lee, O.Y. and Lee, C. and Lee, W. and Kim, K.H. and Kim, S. and Lee, H.Y. and Ullapu, P.R. and Goo, M.J. and Lee, H. and Oh, Y. and Choi, S.H. and Cho, J. and Choi, S.J. and Lee, D.Y. and Jeon, S.H. and Ryu, K.M. and Kim, M.K.},
title = {SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117618},
doi = {10.1016/j.ejca.2026.117618}
}
EUVIMED